Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer

Authors:

Abstract
Prostate cancer is the most commonly diagnosed cancer in men in the US,1 with approximately 70% of patients with a new diagnosis having localized disease.2 Based on National Comprehensive Cancer Network treatment guidelines, active surveillance (AS) is a recommended management option for patients with clinically localized very low-risk, low-risk, or intermediate-risk prostate cancer.3 Patients who are undergoing or are eligible to undergo AS who opt for treatment with a definitive therapy, such as radical prostatectomy, external beam radiation therapy, or brachytherapy, may experience adverse effects, including sexual and voiding dysfunction.3 The decision for treatment intervention is influenced by various factors, including pathological upgrading of disease, grade reclassification, and patient well-being. Biopsy type may influence disease assessment, with some studies showing an exclusion of men from AS protocols because of disease reclassification following a multiparametric magnetic resonance imaging (mpMRI)–targeted biopsy.4

This publication has 11 references indexed in Scilit: